The functional polymorphism methionine synthase (MTR) c.2756A4G (D919G) has been reported to modify the risk of vascular disease and to promote disease-free longevity. In 714 individuals from 187 families, blood pressure was measured, antihypertensive medication recorded and MTR genotype determined. A significant association of the MTR polymorphism with diastolic blood pressure was found which might explain the beneficial effects of its G-allele on vascular disease and disease-free longevity and could be a basis for novel antihypertensive strategies.
The enzyme 5-methyltetrahydrofolate-homocysteine-S-methyltransferase (MTR; enzyme commission EC 2.1.1.13) catalyzes the remethylation of homocysteine to methionine. The G allele of the functional missense dimorphism MTR c.2756A4G (D919G) has been controversially reported to influence plasma homocysteine levels as well as the risk of vascular disease. [1] [2] [3] [4] [5] We found that the G-allele promotes disease-free longevity, but the underlying mechanism remained unknown. 6 As the G-allele was found to be under-represented in 164 patients with essential juvenile hypertension as opposed to 173 controls, 7 we re-evaluated 714 individuals from a family-based study on atherosclerosis 8 to test the hypothesis that the MTR genotype influences blood pressure.
A total of 714 individuals (48% female; age in years7standard deviation: 48.5715.8) from 187 families of Caucasian origin from an ongoing hospital-and family-based study on atherosclerosis 8 were included: 187 consecutive patients (28% female; age: 64.378.8) with proven carotid artery sclerosis, 139 partners (81% female; age: 61.578.8) and 388 children (52% female; age: 36.278.1).
The MTR c.2756A4G polymorphism was analyzed as published previously. 1 Blood pressure was measured five times with an automated device in supine position, and the values were averaged. Participants were asked for current antihypertensive medication. The influence of the MTR genotype on systolic and diastolic blood pressure was analyzed by multiple linear regression analysis with age and gender as covariables. Additionally, index patients, partners and children were analyzed separately. In w 2 tests (Pearson), the prevalence of the MTR genotypes in the quartiles of individuals with highest versus lowest blood pressure was analyzed. This study was approved by the local ethics committee. All subjects gave informed written consent.
The Table 1 ). The MTR polymorphism did not significantly influence plasma homocysteine levels (not shown). Separate analysis of individuals not on antihypertensive medication revealed a significant effect of the MTR genotype on diastolic blood pressure in this group, whereas there was no significant effect in the smaller group of treated individuals ( Table 1) . Analysis of extreme groups revealed that the distribution of the MTR genotypes significantly differed between the quartiles of individuals with the highest versus the lowest diastolic blood pressure. There was no such effect on systolic blood pressure (Table 1) .
Arterial hypertension is an important risk factor for cardio-and cerebrovascular disease. In our study sample, we found a significant association of the MTR c.2576A4G polymorphism with diastolic blood pressure. Probands with the AA genotype had the highest diastolic blood pressure values, followed by those with the AG genotype, and probands with the GG genotype had the lowest diastolic blood pressure suggesting a gene-dosage effect. The MTR polymorphism was reported to be associated with blood pressure response to the angiotensin-converting enzyme inhibitor benazepril in Chinese hypertensive patients. 9 To rule out the possibility that the MTR genotype exerts its effect only by altering the efficacy of antihypertensive drugs we performed a subgroup analysis showing a significant effect in untreated individuals. The association of the G-allele with lower diastolic blood pressure is in accordance with the study of Kahleova et al., 7 who found that carriers of the G-allele of the MTR c.2756A4G polymorphism had a reduced risk of juvenile hypertension. Moreover, the possible influence on diastolic blood pressure may be a functional basis for the reported associations of the G-allele with a reduced risk of recurrent cardiovascular events and with disease-free longevity. 4, 6 The mechanisms by which the MTR genotype influences diastolic blood pressure, but apparently not systolic blood pressure, are unknown. However, MTR is a key enzyme of homocysteine metabolism, and an impairment of homocysteine metabolism can lead to the accumulation of asymmetric dimethyl-L-arginine, which is an endogenous inhibitor of NO synthase. 10 As NO is the most important vasodilatator, this coherence may be an explanation for the effect of the MTR polymorphism on blood pressure. Recently, Brett et al.
11 found a significant effect of methionine loading on diastolic blood pressure during exercise resulting in higher diastolic blood pressure. Considering this, the availability of methionine might also be a possible underlying mechanism of the polymorphism's influence on blood pressure. The association of the MTR polymorphism with diastolic blood pressure should be analyzed in another independent population. If confirmed, the functional consequences of this polymorphism on enzyme activity and metabolism should be analyzed to explore possible approaches for novel antihypertensive strategies. 
